Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patritumab deruxtecan - Daiichi Sankyo Company

X
Drug Profile

Patritumab deruxtecan - Daiichi Sankyo Company

Alternative Names: HER3-DXd; MK-1022; Patritumab-DX-8951 conjugate; U3-1402; U3-1402a

Latest Information Update: 30 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Merck & Co; SCRI Development Innovations; SOLTI Breast Cancer Research Group
  • Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Phase I/II HER2 positive breast cancer

Most Recent Events

  • 25 Apr 2024 Samsung Medical Center plans a phase II Basket trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in South Korea (IV, Infusion) (NCT06383884)
  • 21 Mar 2024 Phase-I/II clinical trials in HER2-positive-breast-cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in France (IV) (NCT06298084)
  • 21 Mar 2024 Phase-I/II clinical trials in HER2-positive-breast-cancer (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV) (NCT06298084)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top